NYSE · Healthcare
Abbott Laboratories (ABT) stock research
Abbott Laboratories (ABT) is listed on NYSE. Abbott Laboratories reported revenue of $44.3B in the fiscal year that ended on 2025-12-31. Revenue rose 5.7% from the year before. Abbott Laboratories’s net income for that year was $6.5B. The SEC classifies it under Pharmaceutical Preparations. It is incorporated in Illinois. Its most recent SEC filing is Form 8-K (current report), filed on 2026-08-20.
Open ABT in Willow. Filings, fundamentals, recent news — sourced stock research, no recommendation.
Annual financials
As tagged by Abbott Laboratories in its annual reports on SEC EDGAR. The latest year is from Form 10-K, filed on 2026-02-20.
| Fiscal year ended | Revenue | Net income | Diluted EPS | Cash and equivalents |
|---|---|---|---|---|
| 2025-12-31 | $44.3B | $6.5B | $3.72 | $8.5B |
| 2024-12-31 | $42.0B | $13.4B | $7.64 | $7.6B |
| 2023-12-31 | $40.1B | $5.7B | $3.26 | $6.9B |
Recent SEC filings
Filed with the SEC under CIK 0000001800. Every row is read from the filing itself on EDGAR, not from a summary of it.
- 8-K (current report) filed 2026-08-20 · period ending 2026-08-20
- 10-Q (quarterly report) filed 2026-07-28 · period ending 2026-06-30
- 8-K (current report) filed 2026-07-16 · period ending 2026-07-16
- 10-Q (quarterly report) filed 2026-04-29 · period ending 2026-03-31
- 8-K (current report) filed 2026-04-27 · period ending 2026-04-24
- 8-K (current report) filed 2026-04-17 · period ending 2026-04-10
Filing history read from SEC EDGAR on 2026-10-19.
What a Willow brief on ABT checks
- Recent filings and company disclosures.
- TTM fundamentals and valuation context.
- Recent news and market context separated from primary filings.
- Bull case, bear case, key risks, and watch-next items in a non-directional register.
Questions about ABT
- What was Abbott Laboratories’s revenue in the fiscal year ended 2025-12-31?
- $44.3B for the fiscal year that ended on 2025-12-31, as reported in Form 10-K filed on 2026-02-20.
- Was Abbott Laboratories profitable in the fiscal year ended 2025-12-31?
- Yes. It reported net income of $6.5B for the fiscal year that ended on 2025-12-31.
- What were Abbott Laboratories’s diluted earnings per share in the fiscal year ended 2025-12-31?
- $3.72 per diluted share for the fiscal year that ended on 2025-12-31.
- How much cash did Abbott Laboratories hold at the end of the fiscal year ended 2025-12-31?
- $8.5B in cash and cash equivalents on 2025-12-31.
- What is Abbott Laboratories’s most recent SEC filing?
- Form 8-K (current report), filed on 2026-08-20. brief.finance reads it directly from SEC EDGAR.
- When does Abbott Laboratories’s fiscal year end?
- Its SEC registration lists the year end as 31 December. The annual figures on this page cover the fiscal year that ended on 2025-12-31.
- What is Abbott Laboratories’s SEC CIK number?
- 0000001800. EDGAR uses this Central Index Key to identify every filing the company submits.
- What does a Willow brief on ABT include?
- Recent SEC filings, fundamentals and valuation context, price history, and both a bull case and a bear case. Every figure links to the source it came from.
- Does brief.finance say whether to buy or sell ABT?
- No. brief.finance publishes educational research and does not recommend buying, selling, or holding any security.
Primary source paths
- SEC EDGAR company filings search
- Nasdaq market activity page
- brief.finance methodology and source checks
More Healthcare research hubs
- ABBV — AbbVie Inc.
- AMGN — Amgen Inc.
- BIIB — Biogen Inc.
- BMY — Bristol-Myers Squibb Company
- CI — The Cigna Group
- CVS — CVS Health Corporation
- DHR — Danaher Corporation
- ELV — Elevance Health, Inc.
- Browse all Healthcare research hubs
Author and editorial responsibility
By Joseph, Founder and editor, brief.finance. Every brief is generated under a fixed editorial and compliance method operated by Reaktif LLC.
About the author · Disclosures · Stock Directory
Ticker catalog last updated 2026-10-19.